CC BY-NC-ND 4.0 · Pharmacopsychiatry 2024; 57(06): 296-303
DOI: 10.1055/a-2374-2386
Original Paper

Twenty-Three Years of Declining Lithium Use: Analysis of a Pharmacoepidemiological Dataset from German-Speaking Countries

Waldemar Greil    ‡
1   Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Germany
2   Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland
,
Mateo de Bardeci   ‡
2   Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland
3   Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland
,
Nadja Nievergelt
2   Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland
,
Sermin Toto
4   Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany
,
Renate Grohmann
1   Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Germany
,
Johanna Seifert
4   Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany
,
Georgios Schoretsanitis
3   Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland
5   The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
6   Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints
Zoom Image

Abstract

Introduction Pharmacoepidemiological data suggest that lithium prescriptions for bipolar disorder are gradually decreasing, with less attention having been paid to other indications.

Methods We examined lithium prescriptions between 1994 and 2017 in data provided by the Drug Safety in Psychiatry Program AMSP, including psychiatric hospitals in Germany, Austria and Switzerland. We compared lithium use for different diagnoses before and after 2001 and in three periods (T1: 1994–2001, T2: 2002–2009, and T3: 2010–2017).

Results In a total of 158,384 adult inpatients (54% female, mean age 47.4±17.0 years), we observed a statistically significant decrease in lithium prescriptions between 1994–2000 and 2001–2017 in patients with schizophrenia spectrum disorder from 7.7% to 5.1% and in patients with affective disorders from 16.8% to 9.6%. Decreases in use were also observed for diagnostic subgroups: schizoaffective disorder (ICD-10 F25: 27.8% to 17.4%), bipolar disorder (F31: 41.3% to 31%), depressive episode (F32: 8.1% to 3.4%), recurrent depression (F33: 17.9% to 7.5%, all: p<0.001) and emotionally unstable (borderline) personality disorder (6.3% to 3.9%, p=0.01). The results in T1 vs. T2 vs. T3 were for F25: 26.7% vs. 18.2% vs. 16.2%, F32: 7.7% vs. 4.2% vs. 2.7%, F33: 17.2% vs. 8.6% vs. 6.6% and for F31: 40.8% vs. 31.7% vs 30.0%, i. e. there was no further decrease for lithium use in bipolar disorder after 2002. Lithium’s main psychotropic co-medications were quetiapine (21.1%), lorazepam (20.6%), and olanzapine (15.2%).

Discussion In inpatients, the use of lithium has decreased in patients with bipolar disorder and also with various other psychiatric diagnoses.

Keywords

lithium - pharmacoepidemiology - bipolar disorders - polypharmacy - psychopharmacology

‡ equal contribution: Waldemar Greil, Mateo de Bardeci


Supplementary Material



Publication History

Received: 13 March 2024

Accepted after revision: 26 June 2024

Article published online:
22 August 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany